RGLS stock forecast
Our latest prediction for Regulus Therapeutics, Inc.'s stock price was made on the Feb. 18, 2020 when the stock price was at 0.83$.
In the short term (2weeks), RGLS's stock price should outperform the market by 3.94%. During that period the price should oscillate between -11.79% and +20.29%.
In the medium term (3months), RGLS's stock price should outperform the market by 36.16%. During that period the price should oscillate between -47.39% and +68.51%.Get email alerts
About Regulus Therapeutics, Inc.
Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.
At the moment the company generates 7M USD in revenues.
On its last earning announcement, the company reported a loss of -1.83$ per share.
The book value per share is 0.10$
Three months stock forecastFeb. 18, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|